Cardiol Therapeutics (CRDL) Total Non-Current Liabilities (2020 - 2026)

Cardiol Therapeutics' Total Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $3.2 million for Q1 2026.

• Quarterly Total Non-Current Liabilities changed N/A year-over-year to $3.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.2 million (changed N/A YoY) and the FY2023 annual result came in at $3.6 million, down 21.99% from the prior year.
• Total Non-Current Liabilities was $3.2 million for Q1 2026 at Cardiol Therapeutics, down from $5.6 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $5.6 million in Q1 2024 and bottomed at $2.7 million in Q1 2023.
• A 4-year average of $4.0 million and a median of $3.9 million in 2022 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities surged 455.96% — and 2023, when it tumbled 36.29%.
• Cardiol Therapeutics' Total Non-Current Liabilities stood at $4.6 million in 2022, then retreated by 21.99% to $3.6 million in 2023, then jumped by 54.52% to $5.6 million in 2024, then plunged by 42.95% to $3.2 million in 2026.
• Business Quant data shows CRDL's Total Non-Current Liabilities at $3.2 million in Q1 2026, $5.6 million in Q1 2024, and $3.6 million in Q4 2023.